PDGFR
Platelet-derived growth factor receptor
PDGFR (Platelet-derived growth factor receptors) are cell surface tyrosine kinase receptors for members of the platelet-derived growth factor (PDGF) family. PDGF subunits -A and -B are important factors regulating cell proliferation, cellular differentiation, cell growth, development and many diseases including cancer. There are two forms of the PDGFR: PDGFR alpha and PDGFR beta.
PDGFR Isoform Specific Products
All Product Categories
-
PDGFR Inhibitors
(276)
View all products
-
PDGFR Antagonist
(1)
View all products
-
PDGFR Activators
(3)
View all products
-
PDGFR Modulators
(2)
View all products
-
PDGFR Chemical
(1)
View all products
-
PDGFR Degrader
(1)
View all products
-
PDGFR Control
(1)
View all products
-
PDGFR Ligands
(4)
View all products
-
PDGF-R-alpha Proteins
(12)
View all products
-
PDGF-R-beta Proteins
(8)
View all products
-
PDGFR Proteins
(22)
View all products
-
PDGFR Related Products (320)
Related Products (320)
-
Recombinant Proteins (22)
-
Antibodies (5)
-
PDGFR Isoform Comparison
-
WQ-C-401
0 ImagesWQ-C-401 is an orally active platelet-derived growth factor receptor (PDGFR) inhibitor. WQ-C-401 inhibits cell proliferation by blocking PDGFR autophosphorylation in a concentration-dependent manner, with EC50 values of 3.5 nM for PDGFRα Y849 and 5.8 nM for PDGFRβ Y1021. Additionally, WQ-C-401 can inhibit PASMCs proliferation and migration by blocking PDGF-BB-induced ERK1/2 phosphorylation, reducing collagen I synthesis, and increasing α-SMA expression, thereby preventing pulmonary vascular remodeling. WQ-C-401 holds promise for research in the field of pulmonary arterial hypertension.
-
PD-089828
0 ImagesPD-089828 is an ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFR (IC50s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC50=0.18 µM). PD-089828 also inhibits MAPK with an IC50 of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity.
-
PDGFR-IN-1
0 ImagesPDGFR-IN-1 (compound 7m) is a potent and orally active PDGFR (platelet-derived growth factor receptor) inhibitor, with IC50 values of 2.4 and 0.9 nM for PDGFRα and PDGFRβ, respectively. PDGFR-IN-1 displays robust antitumor effects and low toxicity, and can be used to study osteosarcoma.
-
Nintedanib-13C,d3
0 ImagesCat. No.: HY-50904S1Synonyms: BIBF 1120-13C,d3Nintedanib-13C,d3 is the 13C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
-
PDGFRA Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS10254PDGFRA Human Pre-designed siRNA Set A contains three designed siRNAs for PDGFRA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Gint4.T aptamer sodium
0 ImagesCat. No.: HY-160053Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment.
-
Pazopanib-13C,d3 hydrochloride
0 ImagesCat. No.: HY-12009SCAS No.: 1261398-44-0Synonyms: GW786034-13C,d3 hydrochloride
-
Regorafenib-d3
0 ImagesSynonyms: BAY 73-4506-d3Regorafenib-d3 (BAY 73-4506-d3) is a deuterium labeled Regorafenib (HY-10331). Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor.
-
CT52923
0 ImagesCT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
-
Nintedanib-d3
0 ImagesSynonyms: BIBF 1120-d3Nintedanib-d3 is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
-
Sunitinib glucuronate
0 ImagesCat. No.: HY-10255CCAS No.: 1818285-48-1Synonyms: SU 11248 glucuronateSunitinib (SU 11248) glucuronate is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib glucuronate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
-
Sutetinib
0 ImagesSutetinib is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as VEGFR (Ki= 0.009 µM for VEGFR-1/2/3), PDGFR (Ki= 0.008 µM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo.
-
AG 370
0 ImagesCat. No.: HY-116111CAS No.: 134036-53-6
-
Pegpleranib sodium
0 ImagesCat. No.: HY-177655APurity: 98.38%Synonyms: Fovista sodiumPegpleranib (Fovista) sodium is a pegylated DNA aptamer that selectively binds to PDGF-BB and PDGF-AB homodimers and heterodimers, interrupting the interaction with their associated tyrosine kinase receptors.
